Figure 3.
Figure 3. Role for platelet-expressed ENT1 in the ticagrelor-induced increase in platelet VASP-P. Representative immunoblots and bar charts showing VASP-P, VASP, and α-tubulin (internal control) levels in washed platelets after incubation at 37°C with the following: (A-B) No drug, vehicle (0.1% DMSO for 60 minutes), NBMPR (1 µM for 0.5, 5, 10, 15, 30, and 60 minutes), or ticagrelor (10 µM for 0.5, 5, 10, 15, 30, and 60 minutes); n = 5. (C-D) Vehicle (0.1% DMSO), ticagrelor (10 µM), NBMPR (1 µM), ticagrelor (10 µM) + NBMPR (1 µM), ADA (10 µg/mL), ADA (10 µg/mL) + ticagrelor (10 µM), and ADA + NBMPR (1 µM); n = 3. (E) Immunoblots showing expression of ENT1 in platelets and 1321N1 cells, with rat glial cells as negative control. Figure is representative of 3 replicates. Data displayed as mean and SEM. *P < .05; **P < .01; ns, P > .05. Statistical test used was 2-way ANOVA (B). Kilodaltons of molecular size markers are reported on the left or in the middle for panel E.

Role for platelet-expressed ENT1 in the ticagrelor-induced increase in platelet VASP-P. Representative immunoblots and bar charts showing VASP-P, VASP, and α-tubulin (internal control) levels in washed platelets after incubation at 37°C with the following: (A-B) No drug, vehicle (0.1% DMSO for 60 minutes), NBMPR (1 µM for 0.5, 5, 10, 15, 30, and 60 minutes), or ticagrelor (10 µM for 0.5, 5, 10, 15, 30, and 60 minutes); n = 5. (C-D) Vehicle (0.1% DMSO), ticagrelor (10 µM), NBMPR (1 µM), ticagrelor (10 µM) + NBMPR (1 µM), ADA (10 µg/mL), ADA (10 µg/mL) + ticagrelor (10 µM), and ADA + NBMPR (1 µM); n = 3. (E) Immunoblots showing expression of ENT1 in platelets and 1321N1 cells, with rat glial cells as negative control. Figure is representative of 3 replicates. Data displayed as mean and SEM. *P < .05; **P < .01; ns, P > .05. Statistical test used was 2-way ANOVA (B). Kilodaltons of molecular size markers are reported on the left or in the middle for panel E.

Close Modal

or Create an Account

Close Modal
Close Modal